We are living in very exciting times in the context of molecular oncology and in particular in the field of immuno-oncology. A deeper understanding of the molecular mechanisms involved in the interaction between the tumour and the immune system is revealing an attractive set of novel therapeutic approaches to treat cancer.  With some pronounced recent successes in this field, this is fuelling aggressive investigation, leading to new questions and challenges.

One of our most popular conferences, Defence is the Best Attack 2027 will be our sixth on this topic. Participants will learn about the most recent advances in the field of immunotherapy from the basic science to clinical studies, including the identification of novel targets. You will gain an improved understanding of the mechanisms of action of therapeutic interventions, and benefit from discussions about biomarkers of response to treatment and mechanisms of intrinsic and acquired resistance to immunotherapy.